Johnson & Johnson: Onyx Pharmaceuticals (NASDAQ:ONXX) Acquisition Scenario
The market for proteasome inhibitors, which currently stands at $2.3 billion, is experiencing rapid transformation. The launch of Onyx Pharmaceuticals’ Kyprolis, the second-in-class molecule launched in the US in July 2012, comes nine years after the initial approval of Velcade (bortezomib), the first-in-class blockbuster.
View full press release